Stockscreener 앱 받기
0.5929
4.72%
0.0267
시장 영업 전:
.64
0.0471
+7.94%
전일 마감가:
$0.5662
열려 있는:
$0.58
하루 거래량:
427.75K
Relative Volume:
0.46
시가총액:
$29.11M
수익:
-
순이익/손실:
$-151.16M
주가수익비율:
-0.1996
EPS:
-2.97
순현금흐름:
$-130.08M
1주 성능:
+8.75%
1개월 성능:
-16.15%
6개월 성능:
-60.47%
1년 성능:
-95.83%
1일 변동 폭
$0.5376
$0.5973
1주일 범위
$0.5302
$0.5973
52주 변동 폭
$0.46
$17.82
AIx 온콜로지 Stock (ALXO) Company Profile
명칭
Alx Oncology Holdings Inc
전화
650-466-7125
주소
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
ALXO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALXO
Alx Oncology Holdings Inc
|
0.5929 | 29.11M | 0 | -151.16M | -130.08M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.47 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.49 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.87 | 36.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.75 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
252.77 | 25.74B | 3.81B | -644.79M | -669.77M | -6.24 |
AIx 온콜로지 Stock (ALXO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-12-19 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-03-08 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-12-08 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-12-22 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-09-30 | 개시 | Stifel | Buy |
| 2021-05-05 | 재개 | Credit Suisse | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-04-06 | 개시 | UBS | Buy |
| 2021-02-10 | 개시 | H.C. Wainwright | Buy |
| 2020-08-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-08-11 | 개시 | Credit Suisse | Outperform |
| 2020-08-11 | 개시 | Jefferies | Buy |
| 2020-08-11 | 개시 | Piper Sandler | Overweight |
모두보기
AIx 온콜로지 주식(ALXO)의 최신 뉴스
Sei Investments Co. Makes New Investment in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
ALXO stock plunges to 52-week low of $0.48 amid market challenges - Investing.com India
ALXO stock plunges to 52-week low of $0.48 amid market challenges By Investing.com - Investing.com South Africa
ALX Oncology advances new cancer drug into Phase 1 trials By Investing.com - Investing.com South Africa
ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate - GlobeNewswire
ALX Oncology gets FDA nod to begin trial of ALX2004 (ALXO) - Seeking Alpha
FDA clears ALX Oncology’s IND for ALX-2004 - BioWorld MedTech
Alx Oncology Receives Ind Clearance From U.S. FDA For Alx2004 - MarketScreener
ALX Oncology advances new cancer drug into Phase 1 trials - Investing.com
Breakthrough Cancer Drug Gets FDA Green Light: ALX2004 Targets Multiple Solid Tumors - Stock Titan
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
ALXO stock touches 52-week low at $0.65 amid market challenges - Investing.com Australia
Cantor Fitzgerald Raises Earnings Estimates for ALX Oncology - Defense World
ALXO stock plunges to 52-week low of $0.73 amid market challenges - Investing.com Australia
ALXO stock plunges to 52-week low of $0.73 amid market challenges By Investing.com - Investing.com South Africa
ALX Oncology Holdings (ALXO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo
Why ALX Oncology Holdings Inc. (ALXO) Soared on Thursday - MSN
ALXO stock touches 52-week low at $0.89 amid market challenges - Investing.com Australia
ALXO stock touches 52-week low at $0.89 amid market challenges By Investing.com - Investing.com South Africa
Insider Buying: Rekha Hemrajani Acquires 30,000 Shares of ALX On - GuruFocus.com
ALX Oncology Holdings: Balancing Growth Potential and Uncertainty with a Hold Rating - TipRanks
Stifel Nicolaus Lowers ALX Oncology (NASDAQ:ALXO) Price Target to $1.50 - Defense World
ALX Oncology (NASDAQ:ALXO) Earns “Buy” Rating from HC Wainwright - Defense World
Why the Global Cancer Market Could Surpass $900 Billion-And the Stocks Leading the Charge - The Malaysian Reserve
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge - PR Newswire
Sun Valley buying at Canagold Resources (CCM) - The Globe and Mail
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
ALX Oncology (NASDAQ:ALXO) Stock Price Expected to Rise, Piper Sandler Analyst Says - Defense World
Jefferies Financial Group Upgrades ALX Oncology (NASDAQ:ALXO) to “Buy” - Defense World
Stifel cuts ALX Oncology stock target to $1.50, maintains hold By Investing.com - Investing.com Canada
Promising Developments in ALX Oncology’s Clinical Pipeline Justify Buy Rating - TipRanks
Jefferies raises ALX Oncology stock to buy, target to $3 By Investing.com - Investing.com South Africa
ALX Oncology Reports 2024 Financial Results and Updates - TipRanks
Micro-, Small-Cap Firms Dominate Market Rally - Insider Monkey
Alx Oncology Holdings Inc Files For Mixed Shelf Of Up To $364.1 Million -March 06, 2025 at 05:35 pm EST - Marketscreener.com
ALX Oncology Holdings Inc (ALXO) Q4 2024 Earnings: EPS of -$0.55 Beats Estimate, Revenue Matches Forecast - GuruFocus.com
ALX Oncology Holdings Inc reports results for the quarter ended December 31Earnings Summary - TradingView
ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times
ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
ALX Oncology jumps as Jefferies upgrades on upside potential - MSN
ALX Oncology stock jumps as Jefferies upgrades(ALXO:NASDAQ) - Seeking Alpha
This Zscaler Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga
ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 - Barchart
ALX Oncology Cuts 30% Workforce, Eliminates President And CSO Role Amid Pipeline Prioritization - Nasdaq
Jefferies Upgrades ALX Oncology to Buy From Hold, Adjusts Price Target to $3 From $2 - Marketscreener.com
Jefferies Upgrades ALX Oncology Holdings (ALXO) - Nasdaq
ALX Oncology Holdings: Undervalued with Promising Catalysts and Growth Opportunities - TipRanks
Jefferies raises ALX Oncology stock to buy, target to $3 - Investing.com
AIx 온콜로지 (ALXO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
AIx 온콜로지 주식 (ALXO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Pons Jaume | PRESIDENT & CSO |
Feb 19 '25 |
Sale |
1.15 |
1,326 |
1,525 |
579,388 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Feb 19 '25 |
Sale |
1.15 |
2,159 |
2,483 |
170,270 |
| Pinto Shelly | Interim CFO |
Jan 06 '25 |
Sale |
1.80 |
2,221 |
3,998 |
87,902 |
| Pinto Shelly | Interim CFO |
Dec 30 '24 |
Sale |
1.58 |
1,426 |
2,253 |
90,123 |
| Pons Jaume | PRESIDENT & CSO |
Dec 30 '24 |
Sale |
1.58 |
10,796 |
17,060 |
580,714 |
| Hemrajani Rekha | Director |
Dec 02 '24 |
Buy |
1.55 |
30,000 |
46,404 |
33,000 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Aug 14 '24 |
Sale |
2.58 |
564 |
1,455 |
91,549 |
| Randolph Sophia | CHIEF MEDICAL OFFICER |
Aug 14 '24 |
Sale |
2.58 |
1,365 |
3,522 |
325,711 |
| Pons Jaume | PRESIDENT & CSO |
Aug 14 '24 |
Sale |
2.58 |
1,937 |
4,997 |
591,510 |
| Pons Jaume | PRESIDENT & CSO |
Jul 11 '24 |
Option Exercise |
0.99 |
20,000 |
19,800 |
613,447 |
1.00%
자본화:
|
볼륨(24시간):